Arcadia Biosciences, Inc.
For the period ended Jun 30, 2026. Filed Aug 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 13, 2026
RKDA$0.17-0.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
(In thousands, except share data)
| Common Stock · AdditionalPaid-In · Accumulated · TotalStockholders’ | |||||
|---|---|---|---|---|---|
| Shares | Amount | Capital | Deficit | Equity | |
| Balance at December 31, 2025 | 1,373,120 | $65 | $285,292 | $(281,217) | $4,140 |
| Issuance of shares related to common stock warrants and preferred investment options exercise | 683,764 | 1 | 3,114 | — | 3,115 |
| Stock-based compensation | — | — | 15 | — | 15 |
| Net loss | — | — | — | (4,385) | (4,385) |
| Balance at March 31, 2026 | 2,056,884 | $66 | $288,421 | $(285,602) | $2,885 |
| Issuance of June 2026 Pre-Funded Warrants | — | — | 4,000 | — | 4,000 |
| Issuance of shares related to common stock warrants and preferred investment options exercise | 124,831 | — | — | — | — |
| Stock-based compensation | — | — | 14 | — | 14 |
| Net loss | — | — | — | (6,266) | (6,266) |
| Balance at June 30, 2026 | 2,181,715 | $66 | $292,435 | $(291,868) | $633 |
| Common Stock · AdditionalPaid-In · Accumulated · TotalStockholders’ | |||||
|---|---|---|---|---|---|
| Shares | Amount | Capital | Deficit | Equity | |
| Balance at December 31, 2024 | 1,364,940 | $65 | $285,036 | $(278,878) | $6,223 |
| Issuance of shares related to employee stock purchase plan | 2,100 | — | 5 | — | 5 |
| Stock-based compensation | — | — | 78 | — | 78 |
| Net income | — | — | — | 2,599 | 2,599 |
| Balance at March 31, 2025 | 1,367,040 | $65 | $285,119 | $(276,279) | $8,905 |
| Stock-based compensation | — | — | 86 | — | 86 |
| Net loss | — | — | — | (4,458) | (4,458) |
| Balance at June 30, 2025 | 1,367,040 | $65 | $285,205 | $(280,737) | $4,533 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.